Evidence map›Paper›PMID 42099437›Full record

ArticleSegmentation, classification, and synthesis for brain tumors and traumatic brain injuries : MICCAI 2025 Challenges: BraTS-Lighthouse 2025 and AIMS-TBI 2025, held in conjunction with MICCAI 2025, Daejeon, South Korea, September 23, 2025,...2026

Adaptable Segmentation Pipeline for Diverse Brain Tumors with Radiomic-guided Subtyping and Lesion-Wise Model Ensemble.

Daniel Capellán-Martín, Abhijeet Parida, Zhifan Jiang, Nishad Kulkarni, Krithika Iyer, Austin Tapp, Syed Muhammad Anwar, María J Ledesma-Carbayo, Marius George Linguraru

Abstract read
In one paragraph

Article in Segmentation, classification, and synthesis for brain tumors and traumatic brain injuries : MICCAI 2025 Challenges: BraTS-Lighthouse 2025 and AIMS-TBI 2025, held in conjunction with MICCAI 2025, Daejeon, South Korea, September 23, 2025,..., 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Daniel Capellán-MartínSheikh Zayed Institute for Pediatric Surgical Innovation, Children's National Hospital, Washington, DC, USA.
Abhijeet ParidaSheikh Zayed Institute for Pediatric Surgical Innovation, Children's National Hospital, Washington, DC, USA.
Zhifan JiangSheikh Zayed Institute for Pediatric Surgical Innovation, Children's National Hospital, Washington, DC, USA.
Nishad KulkarniSheikh Zayed Institute for Pediatric Surgical Innovation, Children's National Hospital, Washington, DC, USA.
Krithika IyerSheikh Zayed Institute for Pediatric Surgical Innovation, Children's National Hospital, Washington, DC, USA.
Austin TappSheikh Zayed Institute for Pediatric Surgical Innovation, Children's National Hospital, Washington, DC, USA.
Syed Muhammad AnwarSheikh Zayed Institute for Pediatric Surgical Innovation, Children's National Hospital, Washington, DC, USA.
María J Ledesma-CarbayoUniversidad Politécnica de Madrid and CIBER-BBN, ISCIII, Madrid, Spain.
Marius George LinguraruSheikh Zayed Institute for Pediatric Surgical Innovation, Children's National Hospital, Washington, DC, USA.

Funding

Quantitative MRI for Pediatric Optic Pathway Glioma Treatment ResponseUG3CA236536 · NCI · CHILDREN'S HOSP OF PHILADELPHIA · PI AVERY, ROBERT ANDREW, LINGURARU, MARIUS GEORGE · 2020 to 2021
$923k
NCI NIH HHS UG3 CA236536
6 · The paper itself

Abstract

Robust and generalizable segmentation of brain tumors on multi-parametric magnetic resonance imaging (MRI) remains difficult because tumor types differ widely. The BraTS 2025 Lighthouse Challenge benchmarks segmentation methods on diverse high-quality datasets of adult and pediatric tumors: multi-consortium international pediatric brain tumor segmentation (PED), preoperative meningioma tumor segmentation (MEN), meningioma radiotherapy segmentation (MEN-RT), and segmentation of pre- and post-treatment brain metastases (MET). We present a flexible, modular, and adaptable pipeline that improves segmentation performance by selecting and combining state-of-the-art models and applying tumor- and lesion-specific processing before and after training. Radiomic features extracted from MRI help detect tumor subtype, ensuring a more balanced training. Custom lesion-level performance metrics determine the influence of each model in the ensemble and optimize post-processing that further refines the predictions, enabling the workflow to tailor every step to each case. On the BraTS testing sets, our pipeline achieved performance comparable to top-ranked algorithms across multiple challenges. These findings confirm that custom lesion-aware processing and model selection yield robust segmentations yet without locking the method to a specific network architecture. Our method has the potential for quantitative tumor measurement in clinical practice, supporting diagnosis and prognosis.

Indexed as

Brain tumor segmentationMedNeXtMeningiomasMetastasesMRInnU-NetPediatric brain tumorsTumor subtyping

Identifiers

PMID42099437
PMCPMC13148016

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.